---
schema_version: "secwatch.filing_event.v1"
accession: "0001534969-26-000008"
form_type: "8-K"
ticker: "SERA"
cik: "0001534969"
company_name: "SERA PROGNOSTICS, INC."
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:51:12.969329+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sera Prognostics Q4 net loss $7.9M; PRIME study shows 56% reduction in preterm births <32 wks

## Summary
- Q4 2025 net loss $7.9M vs $8.6M Q4 2024; full-year net loss $31.9M vs $32.9M.
- Revenue minimal: $10k Q4, $81k full year; company remains pre-commercial.
- Cash $95.8M at Dec 31, 2025; expects to fund operations through 2028.
- PRIME study published Jan 2026: PreTRM test reduced preterm births <32 wks by 56%, NICU admissions by 20%.
- Completed $57.5M follow-on offering Feb 2025; added CMO Dr. Inglis, CCO Anderson in 2025.

## SEC filing metadata
- accession: 0001534969-26-000008
- form_type: 8-K
- ticker: SERA
- cik: 0001534969
- company_name: SERA PROGNOSTICS, INC.
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534969/000153496926000008/0001534969-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534969/000153496926000008/sera-20260318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534969-26-000008
- JSON: https://secwatch.observer/filing/0001534969-26-000008.json
- Plain text: https://secwatch.observer/filing/0001534969-26-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.